Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>3'-Hydroxypterostilbene

3'-Hydroxypterostilbene

Catalog No.GC35112

3'-Hydroxypterostilbene is a Pterostilbene analogue. 3'-Hydroxypterostilbene inhibits the growth of COLO 205, HCT-116 and HT-29 cells with IC50s of 9.0, 40.2 and 70.9 ?M, respectively. 3'-Hydroxypterostilbene significantly down-regulates PI3K/Akt and MAPKs signaling pathways and effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene can be used for the research of cancer.

Products are for research use only. Not for human use. We do not sell to patients.

3'-Hydroxypterostilbene Chemical Structure

Cas No.: 475231-21-1

Size Price Stock Qty
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways[1]. Apoptosis[1]Autophagy[1]

[1]. Cheng TC, et al. Potent anti-cancer effect of 3'-hydroxypterostilbene in human colon xenograft tumors. PLoS One. 2014 Nov 12;9(11):e111814.

Reviews

Review for 3'-Hydroxypterostilbene

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 3'-Hydroxypterostilbene

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.